Kymera Investor Day Presentation Deck

Pathway IL-1R/TLR JAK/STAT p53 Discovery Pipeline KYMERA What Kymera's Clinical Pipeline Could Look Like in 2026 Program IRAK4 IRAKIMID (IRAK4, Ikaros, Aiolos) STAT3 STAT3 MDM2 Indication(s) HS, AD, RA others MYD88MT DLBCL, Waldenstrom's, others Liquid & Solid Tumors Autoimmune & Fibrotic Diseases Liquid & Solid Tumors Tissue Sparing Biology Several Discovery Programs ©2021 KYMERA THERAPEUTICS, INC. Discovery IND Enabling KT-474 KT-413 KT-253 KT-333 Phase 1 Phases 2/3 Multiple programs in immune-inflammatory and oncology indications to deliver ≥ 1 IND/year KYMERA R&D DAY - December 16th, 2021 = Oncology Rights* KYMERA SANOFI KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA = Immunology-Inflammation PAGE 103

View entire presentation